Literature DB >> 25046523

Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.

Esther Bettiol1, Wouter C Rottier, Maria Dolores Del Toro, Stephan Harbarth, Marc J Bonten, Jesús Rodríguez-Baño.   

Abstract

In a time of increasing antibacterial resistance and limited availability of new antibiotics, clinical studies are much needed to assess treatment options against multidrug-resistant organisms (MDROs). In this review, we describe the clinical challenge caused by MDROs and present recent evidence on how clinical studies may generate quality data to improve antibiotic treatment of MDRO infections. To this aim, we critically assess the current status, gaps and challenges associated with observational and interventional studies performed to assess MDRO treatment options. We address why observational studies are useful, which treatment options for MDRO have been explored by observational studies and how to improve quality and usefulness of observational studies. Furthermore, the utility of clinical pharmacokinetic/pharmacodynamic studies for improving MDRO treatment is described. Finally, we discuss interventional study designs, end points and margins, as well as ethical, logistic and statistical challenges, and current regulatory changes proposed to foster the development of new antibiotics.

Entities:  

Keywords:  antibacterial resistance; antibacterial treatment; clinical trials; epidemiology; interventional; multidrug-resistant organisms; observational; pharmacokinetic/pharmacodynamic; regulatory guidance; study design

Mesh:

Substances:

Year:  2014        PMID: 25046523     DOI: 10.2217/fmb.14.35

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  5 in total

1.  Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.

Authors:  Belén Gutiérrez-Gutiérrez; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Benito Almirante; Luis Martínez-Martínez; Antonio Oliver; Esther Calbo; Carmen Peña; Murat Akova; Johann Pitout; Julia Origüen; Vicente Pintado; Elisa García-Vázquez; Oriol Gasch; Axel Hamprecht; Nuria Prim; Mario Tumbarello; German Bou; Pierluigi Viale; Evelina Tacconelli; Manel Almela; Federico Pérez; Helen Giamarellou; José Miguel Cisneros; Mitchell J Schwaber; Mario Venditti; Warren Lowman; Joaquín Bermejo; Po-Ren Hsueh; Marta Mora-Rillo; Irene Gracia-Ahulfinger; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2016-02-22       Impact factor: 5.790

Review 2.  Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.

Authors:  E Torres; M Delgado; A Valiente; Á Pascual; J Rodríguez-Baño
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-02       Impact factor: 3.267

3.  A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Belén Gutiérrez-Gutiérrez; Salvador Pérez-Galera; Elena Salamanca; Marina de Cueto; Esther Calbo; Benito Almirante; Pierluigi Viale; Antonio Oliver; Vicente Pintado; Oriol Gasch; Luis Martínez-Martínez; Johann Pitout; Murat Akova; Carmen Peña; José Molina; Alicia Hernández; Mario Venditti; Nuria Prim; Julia Origüen; German Bou; Evelina Tacconelli; Mario Tumbarello; Axel Hamprecht; Helen Giamarellou; Manel Almela; Federico Pérez; Mitchell J Schwaber; Joaquín Bermejo; Warren Lowman; Po-Ren Hsueh; Marta Mora-Rillo; Clara Natera; Maria Souli; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

4.  Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.

Authors:  Clara Rosso-Fernández; Jesús Sojo-Dorado; Angel Barriga; Lucía Lavín-Alconero; Zaira Palacios; Inmaculada López-Hernández; Vicente Merino; Manuel Camean; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  BMJ Open       Date:  2015-03-31       Impact factor: 2.692

Review 5.  The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.

Authors:  Hugh Laverty; Pierre Meulien
Journal:  Front Med (Lausanne)       Date:  2019-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.